Eli Lilly's Breakthrough in Oral Diabetes Treatment

This chapter explores the encouraging outcomes of Eli Lilly's phase three trial for an oral GLP-1 medication for diabetes treatment, highlighting its effectiveness and safety compared to injectable options. With hopes for regulatory approval and a promising market forecast, the chapter delves into the potential impact on sales despite recent stock variations.